Abstract:Nanomedicines have achieved several successful clinical applications for cancer therapy over the past decades. To date, numerous nanomedicine formats and design rationales have been proposed to improve pharmaceutical delivery and treatment efficacy. Despite these advances, the achievement of high drug loading and loading efficiencies of drug payloads in nanocarriers remains a technical challenge. In addition, study of the correlation between therapeutic potential and drug loading has been ignored. Here, using a self-assembling dimeric cabazitaxel prodrug, we show that the prodrug can be quantitatively entrapped within clinically approved polymer matrices for intravenous injection and that the drug loading in the nanoparticles (NPs) is tunable. The engineered NPs (NPs1-4) with different drug loading values exhibit dissimilar morphologies, release kinetics, in vitro cytotoxic activity, pharmacokinetic properties, tissue distribution, and in vivo anticancer efficacy and safety profiles. Furthermore, the effect of drug loading on the treatment outcomes was explored through detailed in vitro and in vivo studies. Intriguingly, among the constructed NPs, those comprising poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PLA) copolymers showed substantially prolonged pharmacokinetic properties in the blood circulation, which further promoted their intratumoral delivery and accumulation. Furthermore, the PEG-PLA-composed NPs with high drug loading (~50%) demonstrated favorable efficacy and safety profile in animal models. These data provide convincing evidence that the in vivo performance of a given self-assembling drug is not compromised by high drug loading in nanoplatforms, which may potentially reduce concerns over excipient-associated side effects and immunotoxicities. Overall, our study provides new insight into the rationale for designing more effective and less toxic delivery systems.

Albumin-binding Prodrugs Via Reversible Iminoboronate Forming Nanoparticles for Cancer Drug Delivery.

Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery

Protein Nanoparticles Directed Cancer Imaging and Therapy

Albumin Nanoparticle Encapsulation of Potent Cytotoxic Therapeutics Shows Sustained Drug Release and Alleviates Cancer Drug Toxicity.

Aptamer-functionalized Albumin-Based Nanoparticles for Targeted Drug Delivery

Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery

Application of Albumin in Nanodrugs for Cancer Therapy

Drug-binding albumins forming stabilized nanoparticles for efficient anticancer therapy.

Albumin As a "trojan Horse" for Polymeric Nanoconjugate Transendothelial Transport Across Tumor Vasculatures for Improved Cancer Targeting

Protein-Based Artificial Nanosystems in Cancer Therapy

The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Preparation of Drug-Loaded Albumin Nanoparticles and Its Application in Cancer Therapy

Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy

The Combined Effects of Size and Surface Chemistry on the Accumulation of Boronic Acid-Rich Protein Nanoparticles in Tumors.

Nanoalbumin-prodrug conjugates prepared via a thiolation-and-conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8<SUP>+</SUP> T-cell infiltration

Albumin modified cationic nanocarriers to potentially create a new platform for drug delivery systems.

Enhanced Tumor Delivery and Antitumor Response of Doxorubicin-Loaded Albumin Nanoparticles Formulated Based on a Schiff Base.

Bovine Serum Albumin as a Versatile Platform for Cancer Imaging and Therapy

Revolutionizing breast cancer treatment: Harnessing the potential of albumin nanoparticles as targeted drug delivery vehicles

Protein-Polymer Hybrid Nanoparticles for Drug Delivery